
Medtrum
Medtrum is a diabetes management medical device developer.
Medtrum, founded in April, 2008 and headquartered in Shanghai, is a microelectronics medical device developer. Established by Yang Cuijun, the company has received financings from Sequoia Capital China, BOC Investment, 3E Bioventures and so on. Rivals that have direct and indirect competition with Medtrum globally include Diabeloop, Puyou Technology, Sigrid Therapeutics, Apex Medical, etc.
We-Linking Raised Over CNY 10 Mn in Angel Round
Intraoperative Neurophysiological Monitoring Equipment Developer NeuroFlag Closed An Angel Round
IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives
In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow
May 09, 2024 12:18 PM
ZD Medtech Raised Over CNY 100 Mn in Series B
Smart Powered Bionic Prosthetic Star BionicM Nets Over CNY 10 Mn
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Medical Technology Company MacroLux Nets Nearly CNY 100 Mn in Series A
Fine Vision Completes Angel Financing Round Worth Nearly CNY 50 Mn
YingHe Neuro Raises Over CNY 100 Mn in Angel Round
Equipment Company Keyto Nets Over CNY 100 Mn in Series C
Surgical Robot Platform Company KouTech Nets Over USD 10 Mn in Series A+ Round
Trulive Nets Hundreds of Mns of CNY in pre-Series B Financing Round
LinkZill Nets Tens of Millions of CNY in pre-Series A+
China's Healthcare System is Alarming: Can Medical Cloud Mitigate Structural Problems?
Medical Cloud is a potential mass solution for a nation-level healthcare infrastructure rejuvenation for China to be ready to address the upcoming and current challenges in its healthcare industry.
Apr 15, 2019 09:02 PM
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
East China medicine "liraglutide" goes to sea